Early Fetal Morphology and Biochemical Screening for Chromosomal Abnormalities

Early fetal morphology is performed within 11-13 g.w. and is one of the most important ultrasound examinations throughout pregnancy, indicating the risk of congenital anomalies to the fetus. Together with the fetal morphology, a serum screening test is performed measuring the levels of hormones and proteins that originate from the baby or the placenta. Qualitative amounts of pregnancy-related plasma protein-A (PAPP-A) and human chorionic hormone gonadotropin (beta-hCG) mean that the fetus is at higher risk of a having a genetic abnormality. The presence of abnormalities in biochemical screening does NOT prove the presence of a chromosomal abnormality but statistically increases the risk of such. The absence of abnormalities in biochemical screening does NOT completely rule out a chromosomal abnormality, but significantly reduces the risk of such.

 Non-Invasive DNA Prenatal Test

If biochemical screening data indicates a risk of congenital anomalies, a non-invasive prenatal blood test is recommended. It analyses fetal DNA in the mother's bloodstream to confirm specific chromosome problems, such as Down syndrome. The diagnostic accuracy of this test is 99.9% . It is recommended to all pregnant women whose biochemical screening has shown increased risk of biochemical screening, as well over 35 years of age, with miscarriages and prior deliveries of a baby with birth defects. See more

Screening for Sexually Transmitted Infections

Within the first prenatal visit, each pregnant woman should be tested for the presence of urogenital infections. The presence of the latter is associated with a high risk of miscarriage and neonatal infection. The list of minimum number of pathogens that need to be tested is recommended by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), and includes testing for syphilis, chlamydia, hepatitis B, gonorrhea and HIV. See more


Second Trimester Screening Tests

Fetal Morphology

A more detailed ultrasound is performed within the second trimester, from the 19th to the 23rd week of pregnancy. This fetal morphology is extremely important as it examines for structural abnormalities of the fetus.

Triple/Quadruple Biochemical Screening for Chromosomal Abnormalities

Triple biochemical screening is performed within 15th- 20th g.w.  It measures the levels of three or four substances in a pregnant woman's blood: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG) and estriol (uE3). With the test for the hormone inhibin A added, the test is called a quadruple screening. The levels of these substances help the doctor understand the baby's risk of having certain birth defects, such as Down syndrome, spina bifida or anencephaly. The accuracy of  these tests in not high enough to detect whether the baby has a birth defect. Only DNA tests can provide definite diagnosis. See more

Screening for Gestational Diabetes 

The glucose screening test checks for gestational diabetes - a condition that can be developed during pregnancy. The condition is usually temporary and goes away after pregnancy. A pregnant woman can develop gestational diabetes, even if she did not have diabetes prior her pregnancy. Performing a genetic test for predisposition to gestational diabetes can provide useful preliminary information for timely prevention of the disease.

Sexually Transmitted Diseases & Pregnancy

If left untreated, sexually transmitted infections can cause serious problems for both mother and child

PCR analysis is the gold standard for diagnosing most sexually transmitted infections. See more

NIFTY Pro® - fast, safe and accurate screening for the most common genetic abnormalities

Compared to other non-invasive methods such as biochemical screening and fetal morphology NIFTY Pro® provides unmatched 98% accuracy in the detection of genetic defects

Third Trimester Screening Tests
Group B Streptococcus (GBS)

Group B streptococcus (strep) is a type of bacteria that can cause serious infections in pregnant women and newborns. It can be found in the mouth, throat, digestive tract, urinary tract, and in genial area of adult women. 

The vaginal presence of GBS in non-pregnant women is usually not clinically relevant and is asymptomatic. However, this can be very dangerous for a naturally delivered newborn baby who have yet to have a stable immune system.

GBS & Reproductive Failure

GBS bacteria can cause miscarriages, stillbirths and premature births.  Since many different factors can lead to stillbirth or premature birth or miscarriage, in most cases the cause is not investigated.

Neonatal GBS Infection

GBS can cause serious infections in babies exposed to the bacterium during birth. GBS most commonly causes bacteremia, sepsis, pneumonia and meningitis in newborns. GBS can be lethal to the newborn, but there are steps pregnant women can take to protect their babies.

GBS test - Prevention in Newborns

The American College of Obstetricians and Gynecologists (ACOG) and American College of Nurse-Midwives (ACNM) recommend women get tested for GBS bacteria when they are 36 through 37 weeks pregnant. Women who test positive for GBS  are treated with antibiotic treatment to reduce the risk of the baby becoming infected with GBS.

Modern Laboratory Practices
Prenatal Care

 The mission of the Prenatal Care Department at GENICA is to help for a successful pregnancy by preventing diseases that put at risk pregnant women and newborns through provision of up-to-date information, medical research and scientific data.

The specific goals of the department are the promotion of reproductive health and primary prevention.

See Our Tests